This Article Full Text Full Text (PDF) Supplemental material Other Versions of this Article: JVI.00227-08v1 82/21/10684    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Sinn, P. L. Articles by McCray, P. B. PubMed PubMed Citation Articles by Sinn, P. L. Articles by McCray, P. B., Jr.

 Previous Article  |  Next Article 

Journal of Virology, November 2008, p. 10684-10692, Vol. 82, No. 21
0022-538X/08/$08.00+0     doi:10.1128/JVI.00227-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Lentivirus Vector Can Be Readministered to Nasal Epithelia without Blocking Immune Responses ^,

Program in Gene Therapy, Carver College of Medicine Department of Pediatrics,¹ Dows Institute for Dental Research Department of Periodontics, The University of Iowa, Iowa City, Iowa 52242²

Received 1 February 2008/ Accepted 21 August 2008

For many envisioned applications of lentivirus vectors as tools in respiratory biology and therapeutic gene delivery, the efficiency of gene transfer must be improved. We previously demonstrated stable, persistent (>11 months) in vivo expression following a single application of a feline immunodeficiency virus (FIV)-based lentivirus vector (GP64-FIV) to murine nasal epithelia. Here we investigate the efficacy of repeated administration of lentivirus vectors to the airways. Using quantitative bioluminescent imaging, we found that consecutive daily dosing achieved a linear increase in gene expression and greatly increased the number of epithelial cells targeted. Surprisingly, reporter gene expression also increased additively following each of seven doses of FIV delivered over consecutive weeks (1 dose/week), without the development of systemic or local neutralizing antibodies. This approach enhanced expression of both reporter and therapeutic transgenes. Transduction efficiency achieved following a single dose of FIV expressing mouse erythropoietin was insufficient to increase hematocrit, whereas seven consecutive daily doses significantly increased hematocrit. These unexpected results contrast strikingly with findings reported for adenovirus vectors. Prolonged gene expression has been observed in vivo following a single dose of virus vector; however, depending on the application, repeated administration of vector may be necessary to achieve stable, therapeutic gene expression.

Published ahead of print on 3 September 2008.

Supplemental material for this article may be found at http://jvi.asm.org/.